Increase in pulse rate with semaglutide did not result in increased adverse cardiac events in subjects with type 2 diabetes in the SUSTAIN 6 cardiovascular outcomes trial
Event:
ESC Congress 2018
Topic:
Antidiabetic Pharmacotherapy
Session:
Cardiac patients with comorbidities
